Kurozumi A, et al. – Researchers tried to compare the impacts of Anagliptin (ANA) on serum lipid profile with those of alogliptin (ALO) in type 2 diabetes mellitus (T2DM) outpatients. It was noted that the LDL–C lowering effects of ANA and ALO at 24 weeks were almost similar in patients with T2DM. Nevertheless, the results demonstrated a tendency for a decrease in LDL–C level at 24 weeks in the ANA group, and that such improvement was mediated, at least in part, through the suppression of apoB–100 synthesis.

Methods

• Researchers included 87 participants with T2DM patients who had been treated with DPP4–I for 8 weeks or longer and had low–density lipoprotein cholesterol (LDL–C) level of 120 mg/dl or higher.
• Subjects were switched to either 200 mg/day ANA or 25 mg/day ALO for 24 weeks.

Results

• No significant difference was found in %change in LDL–C level at 24 week between ANA and ALO groups.
• The data indicated that treatment with ANA for 12 weeks significantly decreased LDL–C levels, one of the secondary–end points.
• Results suggested that treatment with ANA for 24 weeks significantly improved apolipoprotein B–100 (apoB–100) levels and the percent change in LDL–C levels at 24 weeks correlated significantly with the percent change in apoB–100 levels in the ANA group.